Michael Case

4.6k total citations · 1 hit paper
63 papers, 2.2k citations indexed

About

Michael Case is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Michael Case has authored 63 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Psychiatry and Mental health, 20 papers in Physiology and 13 papers in Pharmacology. Recurrent topics in Michael Case's work include Dementia and Cognitive Impairment Research (17 papers), Alzheimer's disease research and treatments (16 papers) and Bipolar Disorder and Treatment (12 papers). Michael Case is often cited by papers focused on Dementia and Cognitive Impairment Research (17 papers), Alzheimer's disease research and treatments (16 papers) and Bipolar Disorder and Treatment (12 papers). Michael Case collaborates with scholars based in United States, United Kingdom and Japan. Michael Case's co-authors include S. Corya, T.M. Sanger, Susan D. Briggs, Eric Siemers, Gary D. Tollefson, Mauricio Tohen, David Henley, Karen Sundell, Christopher Carlson and Sherie A. Dowsett and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Applied Physics Letters.

In The Last Decade

Michael Case

62 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of Solanezumab in Preclinical Alzheimer’s Disease

2023 186 citations Reisa A. Sperling, Michael Donohue et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Case United States	25	1.4k	775	769	241	223	63	2.2k
Christopher R. Lines United States	28	865 0.6×	716 0.9×	483 0.6×	107 0.4×	437 2.0×	46	2.6k
H.‐J. Möller Germany	27	1.0k 0.7×	419 0.5×	413 0.5×	273 1.1×	59 0.3×	55	2.6k
Carl Sadowsky United States	29	1.7k 1.2×	1.6k 2.1×	614 0.8×	99 0.4×	82 0.4×	67	3.2k
Richard Harvey United Kingdom	25	1.2k 0.8×	1.2k 1.5×	488 0.6×	62 0.3×	175 0.8×	56	3.3k
Joan Amatniek United States	17	937 0.7×	605 0.8×	196 0.3×	57 0.2×	78 0.3×	25	1.7k
Hillel Grossman United States	22	923 0.7×	767 1.0×	172 0.2×	148 0.6×	28 0.1×	51	2.1k
Sheng‐Min Wang South Korea	23	580 0.4×	178 0.2×	494 0.6×	312 1.3×	41 0.2×	113	1.7k
C. G. Gottfries Sweden	28	594 0.4×	539 0.7×	476 0.6×	173 0.7×	99 0.4×	68	2.1k
David Masur United States	22	2.3k 1.6×	878 1.1×	541 0.7×	39 0.2×	163 0.7×	36	3.4k
A.J.M. Loonen Netherlands	26	916 0.7×	218 0.3×	251 0.3×	286 1.2×	53 0.2×	161	2.4k

Countries citing papers authored by Michael Case

Since Specialization

Citations

This map shows the geographic impact of Michael Case's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Case with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Case more than expected).

Fields of papers citing papers by Michael Case

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Case. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Case. The network helps show where Michael Case may publish in the future.

Co-authorship network of co-authors of Michael Case

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Case. A scholar is included among the top collaborators of Michael Case based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Case. Michael Case is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shcherbinin, Sergey, Ivelina Gueorguieva, Cynthia Evans, et al.. (2023). Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials. Alzheimer s & Dementia. 19(S14). 3 indexed citations

Sperling, Reisa A., Michael Donohue, Rema Raman, et al.. (2023). Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal of Medicine. 389(12). 1096–1107. 186 indexed citations breakdown →

Brandes, Jan Lewis, David Kudrow, Suzanne Klise, et al.. (2019). Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) (P1.10-021). Neurology. 92(15_supplement). 2 indexed citations

Loo, Li Shen, Ira Turner, Michael Case, et al.. (2019). Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurology. 19(1). 191–191. 24 indexed citations

Degenhardt, Elisabeth K., Michael M. Witte, Michael Case, et al.. (2016). Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia. IUScholarWorks (Indiana University). 2 indexed citations

Hochstetler, Helen, Paula T. Trzepacz, Shufang Wang, et al.. (2015). Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline. Publisher. 1 indexed citations

Case, Michael. (2015). Pavel Florensky on space and time. SHILAP Revista de lepidopterología.

Detke, Holland C., et al.. (2014). A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection. BMC Psychiatry. 14(1). 7–7. 15 indexed citations

Katagiri, Hideaki, Mauricio Tohen, David McDonnell, et al.. (2013). Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry. 13(1). 138–138. 16 indexed citations

10.

Hoffmann, Vicki Poole, Michael Case, & Jennie G. Jacobson. (2011). Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine. The Journal of Clinical Psychiatry. 73(2). 216–223. 19 indexed citations

11.

Stauffer, Virginia L., Michael Case, Sara Kollack‐Walker, et al.. (2011). Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research. 130(1-3). 11–19. 31 indexed citations

12.

Degenhardt, Elisabeth K., et al.. (2011). Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination. Journal of Clinical Psychopharmacology. 31(3). 337–340. 3 indexed citations

13.

Stauffer, Virginia L., Michael Case, Bruce J. Kinon, et al.. (2010). Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research. 187(1-2). 42–48. 52 indexed citations

14.

Hoffmann, Vicki Poole, Michael Case, Virginia L. Stauffer, Jennie G. Jacobson, & Robert R. Conley. (2010). Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology. 30(6). 656–660. 16 indexed citations

15.

Levine, Stephen Z., Jonathan Rabinowitz, Michael Case, & Haya Ascher‐Svanum. (2010). Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis. Journal of Clinical Psychopharmacology. 30(4). 446–449. 35 indexed citations

16.

Trivedi, Madhukar H., Michael E. Thase, Olawale Osuntokun, et al.. (2009). An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 70(3). 387–396. 50 indexed citations

17.

Dubé, Sanjay, Gary D. Tollefson, Michael E. Thase, et al.. (2007). Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disorders. 9(6). 618–627. 25 indexed citations

18.

Thase, Michael E., S. Corya, Olawale Osuntokun, et al.. (2007). A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry. 68(2). 224–236. 171 indexed citations

19.

Shelton, Richard C., Douglas J. Williamson, S. Corya, et al.. (2005). Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 66(10). 1289–1297. 130 indexed citations

20.

Keck, Paul E., S. Corya, Lori L. Altshuler, et al.. (2005). Analyses of Treatment-Emergent Mania With Olanzapine/Fluoxetine Combination in the Treatment of Bipolar Depression. The Journal of Clinical Psychiatry. 66(5). 611–611. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact